Cellectar Completes Clinical Trial for Cancer Drug
Posted: March 09, 2010 - 9:30 AM
Cellectar, a Madison company developing a drug to combat cancer, has completed the first Phase 1 clinical trial of its lead compound, 131I-CLR1404. Eight patients with advanced solid tumors were involved in the trial at four U.S. hospitals.
Click Here to read the full article.
Medallion Members
- Platinum
- Silver
- Bronze
